Group 1 - The company, Heptagon Pharmaceuticals-B (02142), has entered into a placement agreement with a placement agent to issue a total of 45.022 million shares at a price of HKD 11.50 per share, conditional upon the agreement [1] - The placement price of HKD 11.50 represents a discount of approximately 9.45% compared to the closing price of HKD 12.70 on August 28, 2025 [1] - If all 45.022 million shares are fully subscribed, the net proceeds are expected to be approximately HKD 511.7 million [1] Group 2 - Approximately 50% of the net proceeds will be allocated for the research and development of innovative drug assets [1] - About 40% of the funds will be used to advance clinical trials for existing pipeline drug assets [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]
和铂医药-B拟折让约9.45%配股 净筹约5.117亿港元